ARTICLE SUMMARY:
On the heels of Fasikl’s successful TRANQUIL study, FDA approves its combination of sophisticated AI and non- to minimally invasive stimulation.
Minneapolis-based start-up Fasikl is transforming neurointerventional capabilities with a broadly applicable platform that decodes neural activity at a more granular level than ever before. Each peripheral nerve contains several bundles of fibers, or axons, known as fascicles, which convey electrical signals to and from the brain. While current imaging and neural monitoring technologies can provide insight into brain function regionally or temporally, no technology has previously been able to capture the discrete signals of individual fascicles, not to mention harness the precision of such data for therapeutic use.
